Clinical Trial Update: Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Sacituzumab Tirumotecan for refractory metastatic or unresectable squamous cell carcinoma of the anus and rectum; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Rectal Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase 2, Sacituzumab Tirumotecan | Phase 2 | Status: NOT_YET_RECRUITING